<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693680</url>
  </required_header>
  <id_info>
    <org_study_id>ZnIMI/2004</org_study_id>
    <nct_id>NCT00693680</nct_id>
  </id_info>
  <brief_title>Zinc Supplementation of Imipramine Therapy</brief_title>
  <official_title>The Role of Zinc in Therapy of Unipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Polish Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examination of the effect of zinc supplementation on imipramine therapy in major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A placebo-controlled, double blind study of zinc supplementation in imipramine therapy was
      conducted in sixty, depressed patients fulfilling the DSM-IV criteria for major depression
      without psychotic symptoms. After a one week washout period, patients were randomized into
      two groups treated with imipramine and receiving once daily either placebo (n=30) or zinc
      supplementation (n=30) for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the effect of zinc vs placebo in imipramine treated depressed patients (CGI, BDI, HADRS, MADRS)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess unwanted side effects in both groups</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zinc + imipramine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo + imipramine</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zincas Forte</intervention_name>
    <description>25 mgZn/day + imipramine (100-200mg/day)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zincas Forte (Farmapol, Poland)</other_name>
    <other_name>Imipramin (Polfarma, Poland)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo + imipramine (100-200mg/day)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Imipramin (Polfarma, Poland)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with fulfilled DSM-IV criteria for moderate or severe depressive episode

          -  one week washout period without any pharmacotherapy

        Exclusion Criteria:

          -  psychotic symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrzej Zieba, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, Collegium Medicum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, Collegium Medicum, Jagiellonian University</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Nowak G, Siwek M, Dudek D, Zieba A, Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol. 2003 Nov-Dec;55(6):1143-7.</citation>
    <PMID>14730113</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>June 9, 2008</last_update_submitted>
  <last_update_submitted_qc>June 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>prof. Gabriel Nowak</name_title>
    <organization>Institute of Pharmacology, Polish Academy of Sciences</organization>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>antidepressant treatment</keyword>
  <keyword>zinc</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

